论文部分内容阅读
Objective:To investigate the expression of PTEN in carcinogenesis and development of endometrial carcinoma.Methods:The expression of PTEN was detected by reverse transcription-polymerase chain reaction(RT-PCR)methods from 24 cases with endometrial carcinoma,10 cases with endometrial atypical hyperplasia,10 cases with endometrial hyperplasia and 10 cases with normal endometrium and by SP immunohistochemical methods from 73 cases with endometrial carcinoma,25 cases with endometrial atypical hyperplasia,71 cases with endometrial hyperplasia and 31 cases with normal endometrium.Results:PTEN expression of both RNA and protein in patients with endometrial carcinoma and endometrial atypical hyperplasia was significantly lower than that of patients with endometrial hyperplasia and normal endometrium.mRNA relative value was 0.35±0.13,0.46±0.11,2.32±0.32,2.45±0.51,respectively.Loss of PTEN expression rates were 66.67%(38/57),76.00%(19/25),5.63%(4/71),0(0/31),repectively.The results were also compared with clinical parameters.Loss of PTEN expression in patients with endometrial carcinoma was significantly related to histological classification(P<0.0001)and differentiation(P<0.05).It was not related to depth of myometrium invasion and clinical stage(P>0.05).Conclusion:Loss of PTEN expression is an early event in endometrial tumorigenesis.Detection of PTEN protein may be a diagnostic biomarker for endometrial precancers and adenocarcinoma.
Objective: To investigate the expression of PTEN in carcinogenesis and development of endometrial carcinoma. Methods: The expression of PTEN was detected by reverse transcription-polymerase chain reaction (RT-PCR) methods from 24 cases with endometrial carcinoma, 10 cases with endometrial atypical hyperplasia , 10 cases with endometrial hyperplasia and 10 cases with endometrial hyperplasia and by SP immunohistochemical methods from 73 cases with endometrial carcinoma, 25 cases with endometrial atypical hyperplasia, 71 cases with endometrial hyperplasia and 31 cases with normal endometrium. Results: PTEN expression of both RNA and protein in patients with endometrial carcinoma and endometrial atypical hyperplasia was significantly lower than that of patients with endometrial hyperplasia and normal endometrium. mRNA relative value was 0.35 ± 0.13, 0.46 ± 0.11, 2.32 ± 0.32, 2.45 ± 0.51, respectively. Loss of PTEN expression rates were 66.67% (38/57), 76.00% (19/25), 5.63% (4/71), 0 (0/31), repectively.The results were also compared with clinical parameters. Loss of PTEN expression in patients with endometrial carcinoma was significantly related to histological classification (P <0.0001) and differentiation (P <0.05) .It was not related to depth of myometrium invasion and clinical stage .Conclusion: Loss of PTEN expression is an early event in endometrial tumorigenesis. Detection of PTEN protein may be a diagnostic biomarker for endometrial precancers and adenocarcinoma.